Oxetorone: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Protected "Oxetorone": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(4 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
{{XXXXX}}
{{CMG}}; {{AE}} {{PB}}
'''''For patient information about Oxetorone, click [[Oxetorone (patient information)|here]].'''''
{{SB}} <sup>®</sup>,
==Overview==
{{Drugbox
{{Drugbox
| verifiedrevid = 444750715
| verifiedrevid = 444750715
Line 15: Line 5:
| width = 180
| width = 180
| alt = Ball-and-stick model
| alt = Ball-and-stick model
| image2 = Oxetorone-3D-balls.png
| image2 = 360px-Oxetorone-3D-balls.png
| alt2 = Ball-and-stick model
| alt2 = Ball-and-stick model
<!--Clinical data-->
<!--Clinical data-->
| tradename =  
| tradename =
| Drugs.com = {{drugs.com|international|oxetorone}}
| Drugs.com = {{drugs.com|international|oxetorone}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| pregnancy_category =
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| legal_status =
| routes_of_administration =  
| routes_of_administration =


<!--Pharmacokinetic data-->
<!--Pharmacokinetic data-->
| bioavailability =  
| bioavailability =
| protein_bound =  
| protein_bound =
| metabolism =  
| metabolism =
| elimination_half-life =  
| elimination_half-life =
| excretion =  
| excretion =


<!--Identifiers-->
<!--Identifiers-->
Line 44: Line 34:
| PubChem = 6436540
| PubChem = 6436540
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| DrugBank =
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = T3XOS33TIQ
| UNII = T3XOS33TIQ
Line 51: Line 41:


<!--Chemical data-->
<!--Chemical data-->
| chemical_formula =  
| chemical_formula =
| C=21 | H=21 | N=1 | O=2
| C=21 | H=21 | N=1 | O=2  
| molecular_weight = 319.40 g/mol
| molecular_weight = 319.40 g/mol
| smiles = CN(C)CCC=C1C2=CC=CC=C2OCC3=C1OC4=CC=CC=C34
| smiles = CN(C)CCC=C1C2=CC=CC=C2OCC3=C1OC4=CC=CC=C34
}}
}}
                    __NOTOC__
{{SI}}
{{CMG}}


'''Oxetorone''' is an [[antimigraine]] agent.<ref name="pmid11139754">{{cite journal |author=Massiou H |title=[Prophylactic treatments of migraine] |language=French |journal=Rev. Neurol. (Paris) |volume=156 Suppl 4 |issue= |pages=4S79–86 |year=2000 |pmid=11139754 |doi= |url=http://www.masson.fr/masson/79997}}</ref>
==Overview==
'''Oxetorone''' ([[International Nonproprietary Name|INN]]), as '''oxetorone fumarate''' ([[United States Adopted Name|USAN]]) (brand names '''Nocertone''', '''Oxedix'''), is a [[serotonin antagonist]], [[antihistamine]], and [[alpha blocker]] used as an [[antimigraine drug]].<ref name="GanellinTriggle1996">{{cite book|author1=C.R. Ganellin|author2=David J. Triggle|title=Dictionary of Pharmacological Agents|url=http://books.google.com/books?id=A0THacd46ZsC&pg=PA1493|date=21 November 1996|publisher=CRC Press|isbn=978-0-412-46630-4|pages=1493–}}</ref><ref name="Publishing2013">{{cite book|author=William Andrew Publishing|title=Pharmaceutical Manufacturing Encyclopedia, 3rd Edition|url=http://books.google.com/books?id=_J2ti4EkYpkC&pg=PA2935-IA131|date=22 October 2013|publisher=Elsevier|isbn=978-0-8155-1856-3|pages=2935–}}</ref><ref name="BoxtelSantoso2008">{{cite book|author1=C.J. van Boxtel|author2=B. Santoso|author3=I.R. Edwards|title=Drug Benefits and Risks: International Textbook of Clinical Pharmacology - Revised 2nd Edition|url=http://books.google.com/books?id=idbvAgAAQBAJ&pg=PA699|date=6 August 2008|publisher=IOS Press|isbn=978-1-60750-345-3|pages=699–}}</ref><ref name="pmid11139754">{{cite journal |author=Massiou H |title=[Prophylactic treatments of migraine] |language=French |journal=Rev. Neurol. (Paris) |volume=156 Suppl 4 |issue= |pages=4S79–86 |year=2000 |pmid=11139754 |doi= |url=http://www.masson.fr/masson/79997}}</ref>


Association with [[hyperprolactinemia]] has been described.<ref name="pmid8980859">{{cite journal |author=Pradalier A |title=Hyperprolactinaemia and depression induced by oxetorone |journal=Cephalalgia |volume=16 |issue=8 |pages=560–1 |date=December 1996 |pmid=8980859 |doi= 10.1046/j.1468-2982.1996.1608560.x|url=http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0333-1024&date=1996&volume=16&issue=8&spage=560}}</ref>
Association with [[hyperprolactinemia]] has been described.<ref name="pmid8980859">{{cite journal |author=Pradalier A |title=Hyperprolactinaemia and depression induced by oxetorone |journal=Cephalalgia |volume=16 |issue=8 |pages=560–1 |date=December 1996 |pmid=8980859 |doi= 10.1046/j.1468-2982.1996.1608560.x|url=http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0333-1024&date=1996&volume=16&issue=8&spage=560}}</ref>
<ref>{{Cite web  | last =  | first =  | title = Oxetorone - Wikipedia, the free encyclopedia | url = http://en.wikipedia.org/wiki/Oxetorone | publisher =  | date =  | accessdate =  }}</ref>


==References==
==References==
{{Reflist|2}}
{{Antimigraine preparations}}


{{Reflist|2}}


[[Antimigraine preparations]]
[[Category:Alpha blockers]]
[[Category:Drugs]]
[[Category:Antimigraine drugs]]
[[Category:H1 receptor antagonists]]
[[Category:Heterocyclic compounds (3 rings)]]
[[Category:Drug]]

Latest revision as of 16:52, 20 August 2015

Oxetorone
Ball-and-stick model
Ball-and-stick model
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
UNII
KEGG
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC21H21NO2
Molar mass319.40 g/mol
3D model (JSmol)
  (verify)

WikiDoc Resources for Oxetorone

Articles

Most recent articles on Oxetorone

Most cited articles on Oxetorone

Review articles on Oxetorone

Articles on Oxetorone in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Oxetorone

Images of Oxetorone

Photos of Oxetorone

Podcasts & MP3s on Oxetorone

Videos on Oxetorone

Evidence Based Medicine

Cochrane Collaboration on Oxetorone

Bandolier on Oxetorone

TRIP on Oxetorone

Clinical Trials

Ongoing Trials on Oxetorone at Clinical Trials.gov

Trial results on Oxetorone

Clinical Trials on Oxetorone at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Oxetorone

NICE Guidance on Oxetorone

NHS PRODIGY Guidance

FDA on Oxetorone

CDC on Oxetorone

Books

Books on Oxetorone

News

Oxetorone in the news

Be alerted to news on Oxetorone

News trends on Oxetorone

Commentary

Blogs on Oxetorone

Definitions

Definitions of Oxetorone

Patient Resources / Community

Patient resources on Oxetorone

Discussion groups on Oxetorone

Patient Handouts on Oxetorone

Directions to Hospitals Treating Oxetorone

Risk calculators and risk factors for Oxetorone

Healthcare Provider Resources

Symptoms of Oxetorone

Causes & Risk Factors for Oxetorone

Diagnostic studies for Oxetorone

Treatment of Oxetorone

Continuing Medical Education (CME)

CME Programs on Oxetorone

International

Oxetorone en Espanol

Oxetorone en Francais

Business

Oxetorone in the Marketplace

Patents on Oxetorone

Experimental / Informatics

List of terms related to Oxetorone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Oxetorone (INN), as oxetorone fumarate (USAN) (brand names Nocertone, Oxedix), is a serotonin antagonist, antihistamine, and alpha blocker used as an antimigraine drug.[1][2][3][4]

Association with hyperprolactinemia has been described.[5]

References

  1. ↑ C.R. Ganellin; David J. Triggle (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 1493–. ISBN 978-0-412-46630-4.
  2. ↑ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
  3. ↑ C.J. van Boxtel; B. Santoso; I.R. Edwards (6 August 2008). Drug Benefits and Risks: International Textbook of Clinical Pharmacology - Revised 2nd Edition. IOS Press. pp. 699–. ISBN 978-1-60750-345-3.
  4. ↑ Massiou H (2000). "[Prophylactic treatments of migraine]". Rev. Neurol. (Paris) (in French). 156 Suppl 4: 4S79–86. PMID 11139754.
  5. ↑ Pradalier A (December 1996). "Hyperprolactinaemia and depression induced by oxetorone". Cephalalgia. 16 (8): 560–1. doi:10.1046/j.1468-2982.1996.1608560.x. PMID 8980859.


Template:Antimigraine preparations

Retrieved from "https://www.wikidoc.org/index.php?title=Oxetorone&oldid=1137184"